Aspen Aerogels Inc. (ASPN) stock plummeted 27.91% in intraday trading on Wednesday, following the company's release of its fourth-quarter 2024 financial results and disappointing guidance for the first quarter of 2025.
While Aspen Aerogels reported better-than-expected Q4 revenue and earnings, beating analysts' estimates, the market reacted negatively to its weak Q1 2025 guidance. The company provided a Q1 revenue guidance range of $75 million to $95 million, significantly lower than the consensus estimate of $104.22 million. Additionally, its Q1 EPS guidance range of ($0.18) to $0.00 fell short of the consensus estimate of $0.08.
Adding to the stock's decline, Aspen Aerogels also announced that it is halting the construction of its Statesboro manufacturing facility, citing the need to focus resources on its existing operations.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。